TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

Benzinga Logo Benzinga By Vandana Singh
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.

Insights
GM   negative

Temporarily laying off 5,500 workers and reassessing electric vehicle output


GSK   neutral

Proactively defending its licensing interests through legal action to protect its investment in Tesaro and the Jemperli drug